MABSERNIS Trademark

Trademark Overview

On Thursday, April 8, 2010, a trademark application was filed for MABSERNIS with the United States Patent and Trademark Office. The USPTO has given the MABSERNIS trademark a serial number of 85009762. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, August 14, 2020. This trademark is owned by Glaxo Group Limited. The MABSERNIS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; and for vaccines
mabsernis

General Information

Serial Number85009762
Word MarkMABSERNIS
Filing DateThursday, April 8, 2010
Status710 - CANCELLED - SECTION 8
Status DateFriday, August 14, 2020
Registration Number4460736
Registration DateTuesday, January 7, 2014
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 19, 2010

Trademark Statements

Goods and ServicesPharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; and for vaccines

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, August 14, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameGlaxo Group Limited
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressBrentford, Middlesex TW89GS
GB
Party NameGlaxo Group Limited
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressBrentford, Middlesex TW89GS
GB
Party NameGlaxo Group Limited
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressGreenford, Middlesex UB60NN
GB

Trademark Events

Event DateEvent Description
Friday, August 14, 2020CANCELLED SEC. 8 (6-YR)
Monday, January 7, 2019COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Tuesday, June 23, 2015TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, January 7, 2014REGISTERED-PRINCIPAL REGISTER
Monday, December 2, 20131(B) BASIS DELETED; PROCEED TO REGISTRATION
Monday, November 18, 2013NOTICE OF ALLOWANCE CANCELLED
Monday, November 18, 2013TEAS DELETE 1(B) BASIS RECEIVED
Friday, June 7, 2013NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, June 6, 2013EXTENSION 5 GRANTED
Friday, May 31, 2013EXTENSION 5 FILED
Friday, May 31, 2013TEAS EXTENSION RECEIVED
Monday, March 25, 2013APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, March 25, 2013TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, March 15, 2013ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, March 15, 2013TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, December 6, 2012NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, December 5, 2012EXTENSION 4 GRANTED
Monday, December 3, 2012EXTENSION 4 FILED
Monday, December 3, 2012TEAS EXTENSION RECEIVED
Tuesday, July 31, 2012NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, July 30, 2012EXTENSION 3 GRANTED
Monday, June 11, 2012EXTENSION 3 FILED
Monday, June 11, 2012TEAS EXTENSION RECEIVED
Tuesday, November 29, 2011NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, November 28, 2011EXTENSION 2 GRANTED
Wednesday, November 23, 2011EXTENSION 2 FILED
Wednesday, November 23, 2011TEAS EXTENSION RECEIVED
Wednesday, June 15, 2011NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, June 14, 2011EXTENSION 1 GRANTED
Thursday, June 9, 2011EXTENSION 1 FILED
Tuesday, June 14, 2011CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, June 9, 2011TEAS EXTENSION RECEIVED
Tuesday, December 14, 2010NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, October 19, 2010OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 19, 2010PUBLISHED FOR OPPOSITION
Friday, September 10, 2010LAW OFFICE PUBLICATION REVIEW COMPLETED
Friday, September 10, 2010APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, September 10, 2010TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, September 10, 2010CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, September 10, 2010ASSIGNED TO LIE
Monday, August 23, 2010TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, August 23, 2010TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, July 14, 2010NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, July 14, 2010NON-FINAL ACTION E-MAILED
Wednesday, July 14, 2010NON-FINAL ACTION WRITTEN
Tuesday, July 13, 2010ASSIGNED TO EXAMINER
Thursday, May 13, 2010TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, April 13, 2010NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, April 12, 2010NEW APPLICATION ENTERED IN TRAM

Related Keywords

mabsernis pharmaceutical treatment substances disorders preparations diseases hormonal neurological gastrointestinal ophthalmic